# US 2010/0168028 A1 · Compositions and methods of using crmp-1 and its fragments for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168028 A1
- Document ID: US20100168028A1
- Status: Published application
- Kind: A1
- Application number: 12/718,997
- Filed: 2010-03-07
- Published: 2010-07-01
- Earliest claimed: 2007-03-23
- Assignees: Advpharma Inc.
- Inventors: HARN-JING TERNG; YI-JEN LEE; WOAN-JEN LEE
- Web page: https://patentgrep.com/patent/US20100168028A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Active fragments of hcrmp1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer and methods of using the same for treating cancer are disclosed. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. Vectors capable of expressing an hcrmp1, variants of hcrmp1, fragments of hcrmp1 and/or variants of fragments of hcrmp1 are also disclosed.

## Claims

### Claim 1

An isolated polypeptide, which is a fragment of CRMP-1 protein that comprises the amino acid sequence of SEQ ID NO: 1, wherein the isolated polypeptide has no longer than 500 amino acid residues in length and is active in inhibiting the proliferation, metastasis, and/or invasion of a cancer cell.

### Claim 2 (depends on 1)

An isolated polypeptide according to claim 1, comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 17, 19, 21, 23, 25, and 39-43.

### Claim 3 (depends on 2)

The isolated polypeptide of claim 2, wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 17 and 39.

### Claim 4 (depends on 1)

An isolated polypeptide according to claim 1, the amino acid sequence of which is selected from the group consisting of SEQ ID NOs: 15, 17, 19, 21, 23, 25, and 39-43.

### Claim 5 (depends on 1)

An isolated polypeptide according to claim 1, the amino acid sequence of which is selected from the group consisting of SEQ ID NOs: 17 and 39.

### Claim 6 (depends on 1)

An isolated polypeptide according to claim 1, which is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 16, 18, 20, 22, 24, 26 and 33-38.

### Claim 7 (depends on 1)

An isolated polypeptide according to claim 1, which is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 18 and 34.

### Claim 8 (depends on 1)

A method of making the isolated polypeptide of claim 1, comprising the step of:
(a) constructing a recombinant vector comprising:
(i) at least one regulatory element; and
(ii) a nucleic acid insert encoding the isolated polypeptide, comprising the nucleotide sequence selected from the group consisting of SEQ ID NOs: 16, 18, 20, 22, 24, 26, 33, 34, 35, 36, 37, and 38, linked in translation frame to the at least one regulatory element;
wherein the vector does not fully encode SEQ ID NO:1, and wherein the isolated polypeptide has no longer than 500 amino acid residues in length and is active in inhibiting the proliferation, metastasis, and/or invasion of a cancer cell; and
(b) transfecting a host cell with the recombinant vector from step (a); and
(c) inducing the expression of the nucleic acid insert in the host cell to obtain the isolated polypeptide.

### Claim 9 (depends on 1)

A fusion protein consisting of:
(a) a protein transduction domain (PTD); and
(b) an isolated polypeptide according to claim 1, operably linked to the PTD.

### Claim 10 (depends on 3)

A fusion protein consisting of:
(a) a protein transduction domain (PTD); and
(b) an isolated polypeptide according to claim 3, operably linked to the PTD.

### Claim 11 (depends on 5)

A fusion protein consisting of:
(a) a protein transduction domain (PTD); and
(b) an isolated polypeptide according to claim 5, operably linked to the PTD.

### Claim 12 (depends on 1)

A composition comprising a therapeutically effective amount of an isolated polypeptide according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 2)

A composition comprising a therapeutically effective amount of an isolated polypeptide according to claim 2 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 3)

A composition comprising a therapeutically effective amount of an isolated polypeptide according to claim 3 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 4)

A composition comprising a therapeutically effective amount of an isolated polypeptide according to claim 4 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 5)

A composition comprising a therapeutically effective amount of an isolated polypeptide according to claim 5 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 6)

A composition comprising a therapeutically effective amount of an isolated polypeptide according to claim 6 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 12)

A method of inhibiting the proliferation, metastasis, and/or invasion of a cancer cell in a patient in need thereof, comprising the step of administering an effective amount of the composition of claim 12.

### Claim 19 (depends on 14)

A method of inhibiting the proliferation, metastasis, and/or invasion of a cancer cell in a patient in need thereof, comprising the step of administering an effective amount of the composition of claim 14.

### Claim 20 (depends on 16)

A method of inhibiting the proliferation, metastasis, and/or invasion of a cancer cell in a patient in need thereof, comprising the step of administering an effective amount of the composition of claim 16.
